Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma

NCT03757689 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT03757689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03757689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 6, 2019
Completion date
February 1, 2027
Enrollment
86 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma